MedPath

Evaluation of the safety of transgenic rice containing peptides from Japanese cedar pollen allergens

Phase 1
Conditions
Healthy Individual
Registration Number
JPRN-UMIN000010212
Lead Sponsor
Department of Molecular Immunology, Institute of DNA Medicine, The Jikei University, School of Medicine.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
18
Inclusion Criteria

Not provided

Exclusion Criteria

1) A person with a BMI values under 17, or over 28. 2) A person who has hay fever and/or medical history of other allergic disorder. 3) Preliminarily examined positive at more than one of followings; Rhinoscopic examination, Nasal mucosa test, Nasal discharged eosinophil, Intradermal reaction and cedar-pollen specific IgE antibody. 4) A person with a medical history of rice allergy. 5) A person who has a disease which is undergoing treatment 6) A person with serious conditions such as diabetes, hepatic disease, and cardiac disease. 7) A person preliminarily ruled unfit to become a clinical study patient. 8) A person already in another clinical test when this clinical test begins. 9) A person who's presently breastfeeding, in pregnancy, or planning/wishing to be a pregnant during a period of clinical test. 10) A person whom trial investigator has assessed as mismatched participant.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath